| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.
|
J Clin Oncol
|
2003
|
8.95
|
|
2
|
Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer.
|
J Clin Oncol
|
2005
|
4.02
|
|
3
|
Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
|
J Clin Oncol
|
2005
|
3.79
|
|
4
|
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas.
|
J Clin Oncol
|
2005
|
3.62
|
|
5
|
Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.
|
J Natl Cancer Inst
|
2005
|
2.74
|
|
6
|
Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
|
J Clin Oncol
|
2007
|
2.51
|
|
7
|
Significance of histological response to preoperative chemoradiotherapy for pancreatic cancer.
|
Ann Surg Oncol
|
2005
|
1.88
|
|
8
|
Concurrent chemoradiotherapy in resected extrahepatic cholangiocarcinoma.
|
Int J Radiat Oncol Biol Phys
|
2008
|
1.83
|
|
9
|
Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107.
|
J Clin Oncol
|
2008
|
1.74
|
|
10
|
A phase I first-in-human study of TRC105 (Anti-Endoglin Antibody) in patients with advanced cancer.
|
Clin Cancer Res
|
2012
|
1.64
|
|
11
|
Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from two randomized clinical trials.
|
J Clin Oncol
|
2008
|
1.48
|
|
12
|
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.
|
Cancer Immunol Immunother
|
2008
|
1.39
|
|
13
|
Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies.
|
J Cancer Res Clin Oncol
|
2009
|
1.38
|
|
14
|
Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results.
|
Int J Radiat Oncol Biol Phys
|
2007
|
1.28
|
|
15
|
Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experience.
|
Int J Radiat Oncol Biol Phys
|
2005
|
1.28
|
|
16
|
Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure.
|
Clin Cancer Res
|
2012
|
1.25
|
|
17
|
Phase I safety, pharmacokinetics, and inhibition of SRC activity study of saracatinib in patients with solid tumors.
|
Clin Cancer Res
|
2010
|
1.23
|
|
18
|
Increased toxicity with gefitinib, capecitabine, and radiation therapy in pancreatic and rectal cancer: phase I trial results.
|
J Clin Oncol
|
2006
|
1.21
|
|
19
|
Anti-VEGF therapies in the clinic.
|
Cold Spring Harb Perspect Med
|
2012
|
1.20
|
|
20
|
Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases.
|
J Am Coll Surg
|
2007
|
1.19
|
|
21
|
An intervention to improve cancer patients' understanding of early-phase clinical trials.
|
IRB
|
2009
|
1.18
|
|
22
|
Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study.
|
Oncologist
|
2012
|
1.18
|
|
23
|
Prognostic and predictive blood-based biomarkers in patients with advanced pancreatic cancer: results from CALGB80303 (Alliance).
|
Clin Cancer Res
|
2013
|
1.18
|
|
24
|
Health-related quality of life impact of bevacizumab when combined with irinotecan, 5-fluorouracil, and leucovorin or 5-fluorouracil and leucovorin for metastatic colorectal cancer.
|
Oncologist
|
2008
|
1.11
|
|
25
|
Research participants' high expectations of benefit in early-phase oncology trials: are we asking the right question?
|
J Clin Oncol
|
2012
|
1.11
|
|
26
|
Duodenal adenocarcinoma: patterns of failure after resection and the role of chemoradiotherapy.
|
Int J Radiat Oncol Biol Phys
|
2007
|
1.10
|
|
27
|
Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer.
|
Semin Oncol
|
2003
|
1.07
|
|
28
|
Understanding and targeting resistance to anti-angiogenic therapies.
|
J Gastrointest Oncol
|
2013
|
1.05
|
|
29
|
A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer.
|
Oncologist
|
2011
|
1.05
|
|
30
|
Analysis of age, estimated creatinine clearance and pretreatment hematologic parameters as predictors of fludarabine toxicity in patients treated for chronic lymphocytic leukemia: a CALGB (9011) coordinated intergroup study.
|
Cancer Chemother Pharmacol
|
2002
|
1.02
|
|
31
|
Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab.
|
Cancer Med
|
2013
|
1.02
|
|
32
|
Does preoperative therapy optimize outcomes in patients with resectable pancreatic cancer?
|
J Surg Oncol
|
2012
|
1.00
|
|
33
|
Targeted therapy of colorectal cancer: clinical experience with bevacizumab.
|
Oncologist
|
2004
|
0.97
|
|
34
|
Targeted inhibition of VEGF receptor 2: an update on ramucirumab.
|
Expert Opin Biol Ther
|
2013
|
0.96
|
|
35
|
Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA.
|
Cancer Invest
|
2003
|
0.95
|
|
36
|
A phase II study of capecitabine, oxaliplatin, bevacizumab and cetuximab in the treatment of metastatic colorectal cancer.
|
Anticancer Res
|
2011
|
0.95
|
|
37
|
Radiotherapy in the treatment of patients with unresectable extrahepatic cholangiocarcinoma.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.93
|
|
38
|
A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE).
|
Cancer Chemother Pharmacol
|
2010
|
0.93
|
|
39
|
Complete pathological response to bevacizumab and chemoradiation in advanced rectal cancer.
|
Nat Clin Pract Oncol
|
2007
|
0.92
|
|
40
|
Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer.
|
Oncologist
|
2012
|
0.92
|
|
41
|
Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer.
|
Clin Cancer Res
|
2013
|
0.91
|
|
42
|
Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules.
|
Clin Cancer Res
|
2010
|
0.91
|
|
43
|
Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors.
|
Invest New Drugs
|
2012
|
0.91
|
|
44
|
Clinical outcomes of patients with advanced gastrointestinal stromal tumors: safety and efficacy in a worldwide treatment-use trial of sunitinib.
|
Cancer
|
2015
|
0.90
|
|
45
|
A clinical model of dermal wound angiogenesis.
|
Wound Repair Regen
|
2003
|
0.88
|
|
46
|
Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor.
|
Clin Cancer Res
|
2003
|
0.88
|
|
47
|
Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer.
|
Int J Radiat Oncol Biol Phys
|
2007
|
0.87
|
|
48
|
A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2012
|
0.86
|
|
49
|
The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer.
|
Int J Gastrointest Cancer
|
2002
|
0.86
|
|
50
|
A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer.
|
Clin Colorectal Cancer
|
2011
|
0.84
|
|
51
|
Phase I study of dasatinib in combination with capecitabine, oxaliplatin and bevacizumab followed by an expanded cohort in previously untreated metastatic colorectal cancer.
|
Invest New Drugs
|
2013
|
0.84
|
|
52
|
Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2012
|
0.84
|
|
53
|
Modulation of circulating protein biomarkers following TRC105 (anti-endoglin antibody) treatment in patients with advanced cancer.
|
Cancer Med
|
2014
|
0.83
|
|
54
|
Effects of the combination of TRC105 and bevacizumab on endothelial cell biology.
|
Invest New Drugs
|
2014
|
0.82
|
|
55
|
A phase I study of ABT-510 plus bevacizumab in advanced solid tumors.
|
Cancer Med
|
2013
|
0.82
|
|
56
|
Ziv-aflibercept: binding to more than VEGF-A--does more matter?
|
Nat Rev Clin Oncol
|
2012
|
0.82
|
|
57
|
Palliative treatment of metastatic colorectal cancer: what is the optimal approach?
|
Curr Oncol Rep
|
2014
|
0.82
|
|
58
|
Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer.
|
Semin Oncol
|
2005
|
0.81
|
|
59
|
Development and utilization of a combined LC-UV and LC-MS/MS method for the simultaneous analysis of tegafur and 5-fluorouracil in human plasma to support a phase I clinical study of oral UFT®/leucovorin.
|
J Chromatogr B Analyt Technol Biomed Life Sci
|
2012
|
0.80
|
|
60
|
A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors.
|
Anticancer Res
|
2010
|
0.80
|
|
61
|
The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors.
|
BMC Cancer
|
2013
|
0.80
|
|
62
|
Bevacizumab exposure beyond first disease progression in patients with metastatic colorectal cancer: analyses of the ARIES observational cohort study.
|
Pharmacoepidemiol Drug Saf
|
2014
|
0.79
|
|
63
|
Maintenance therapy for first-line metastatic colorectal cancer: activity and sustainability.
|
Oncologist
|
2012
|
0.78
|
|
64
|
A phase II study of capecitabine, oxaliplatin, and bevacizumab in the treatment of metastatic esophagogastric adenocarcinomas.
|
Oncologist
|
2013
|
0.78
|
|
65
|
Phase I dose escalation study of gemcitabine plus irinotecan in advanced solid tumors.
|
Anticancer Res
|
2009
|
0.78
|
|
66
|
A Phase I trial of preoperative eniluracil plus 5-fluorouracil and radiation for locally advanced or unresectable adenocarcinoma of the rectum and colon.
|
Int J Radiat Oncol Biol Phys
|
2004
|
0.78
|
|
67
|
Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic: A Decade of Progress.
|
Cancer J
|
2015
|
0.78
|
|
68
|
Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2010
|
0.78
|
|
69
|
Dual inhibition of αV integrins and Src kinase activity as a combination therapy strategy for colorectal cancer.
|
Anticancer Drugs
|
2013
|
0.77
|
|
70
|
Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective study.
|
J Gastrointest Surg
|
2008
|
0.76
|
|
71
|
A phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors.
|
Invest New Drugs
|
2014
|
0.76
|
|
72
|
Registries and randomized trials in assessing the effects of bevacizumab in colorectal cancer: is there a common theme?
|
J Clin Oncol
|
2012
|
0.76
|
|
73
|
The role of targeted therapy in the treatment of colorectal cancer.
|
Clin Adv Hematol Oncol
|
2006
|
0.76
|
|
74
|
Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors.
|
Invest New Drugs
|
2014
|
0.75
|
|
75
|
Treatment of palmar-plantar erythrodysesthesia (PPE) with topical sildenafil: a pilot study.
|
Support Care Cancer
|
2014
|
0.75
|
|
76
|
A Phase I study of capecitabine, carboplatin, and paclitaxel with external beam radiation therapy for esophageal carcinoma.
|
Int J Radiat Oncol Biol Phys
|
2006
|
0.75
|
|
77
|
Is bevacizumab effective and safe in combination with chemotherapy in patients with colorectal cancer?
|
Nat Clin Pract Oncol
|
2007
|
0.75
|
|
78
|
A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer.
|
Cancer Invest
|
2011
|
0.75
|
|
79
|
Metastatic ampullary adenocarcinoma presenting as a hydrocele: a case report.
|
JOP
|
2014
|
0.75
|
|
80
|
A phase I study of eniluracil/5-FU in combination with radiation therapy for potentially resectable and/or unresectable cancer of the pancreas and distal biliary tract.
|
Cancer Invest
|
2006
|
0.75
|
|
81
|
Angiogenesis pathway inhibitors.
|
Cancer Chemother Biol Response Modif
|
2005
|
0.75
|
|
82
|
A phase I study of UFT/leucovorin, carboplatin, and paclitaxel in combination with external beam radiation therapy for advanced esophageal carcinoma.
|
Int J Radiat Oncol Biol Phys
|
2007
|
0.75
|
|
83
|
A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors.
|
Cancer Chemother Pharmacol
|
2014
|
0.75
|
|
84
|
Angiogenesis inhibition in the treatment of colorectal cancer Part 3 of a 3-part series: targeting VEGF--current and future research directions.
|
Clin Adv Hematol Oncol
|
2005
|
0.75
|